Table 3.
Treatment duration |
Total dose |
Total | ||||
---|---|---|---|---|---|---|
First site of failure | 5-week | 6-week | ≤70.0 GyE | >70.0 GyE | ||
SqCC | Locoregional failure | 7 (36.4%) | 1 (7.1%) | 8 (34.8%) | 0 (0%) | 9 (25.0%) |
Distant failure | 4 (18.2%) | 9 (64.3%) | 11 (47.8%) | 3 (23.1%) | 13 (36.1%) | |
PALN failure | 1 (4.5%) | 8 (57.1%) | 6 (26.9%) | 3 (23.1%) | 9 (25.0%) | |
Total | 22 | 14 | 23 | 13 | 36 | |
AC | Locoregional failure | 18 (32.7%) | 0 | 6 (35.3%) | 12 (31.6%) | 18 (32.7%) |
Distant failure | 27 (49.1%) | 0 | 6 (35.3%) | 21 (55.3%) | 27 (49.1%) | |
PALN failure | 10 (18.2%) | 0 | 4 (23.5%) | 6 (15.8%) | 10 (18.2%) | |
Total | 55 | 0 | 17 | 38 | 55 |